Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report)’s share price hit a new 52-week high during trading on Wednesday after Bank of America raised their price target on the stock from $18.00 to $21.

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Hims & Hers, a health and wellness platform, is set to introduce at-home lab testing capabilities through the acquisition of ...

There are wonders of the visual world—this week, dive into the hidden beauty of the plants that keep us alive, the less ...

Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

This is the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...

There are wonders of the visual world—this week, dive into the hidden beauty of the plants that keep us alive, the less ...

The VanEck ETF seeks out stocks with the "highest degree of positive investor sentiment." Super Micro (SMCI), Palantir (PLTR), Hims & Hers Health (HIMS), Ast SpaceMobile (ASTS) and Meta Platforms ...